Intech Biopharm Corporation reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 6.86 million compared to TWD 2.57 million a year ago. Net loss was TWD 85.86 million compared to TWD 75.06 million a year ago. Basic loss per share from continuing operations was TWD 0.73 compared to TWD 0.65 a year ago. Diluted loss per share from continuing operations was TWD 0.73 compared to TWD 0.65 a year ago.
For the nine months, sales was TWD 20.4 million compared to TWD 19.43 million a year ago. Net loss was TWD 239.79 million compared to TWD 228.69 million a year ago. Basic loss per share from continuing operations was TWD 2.05 compared to TWD 1.97 a year ago. Diluted loss per share from continuing operations was TWD 2.05 compared to TWD 1.97 a year ago.